Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT06578949 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria
PNH

Interventions

DRUG: Ravulizumab

Sponsor

Alexion Pharmaceuticals, Inc.